Implementing an Efficient Allogeneic Cell Therapy Manufacturing Strategy

March 14, 2023

Marty Giedlin, vice president and head of technology operations at Senti Bio, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, to share his experiences and provide advice on how allogeneic cell therapy companies can implement better manufacturing strategies. He discusses understanding and managing manufacturing expectations, letting biology drive strategic operations, and why data must drive chemistry, manufacturing, and controls. Giedlin also outlines how to best characterize starting materials, why a one-size-fits-all approach to process manufacturing is unrealistic, his predictions for the industry over the next five years, and his work developing NK-CAR treatments for various cancer cells.

GUEST BIO

Marty Giedlin, Ph.D., Senior Vice President and Head of Technical Operations, Senti Bio
Dr. Marty Giedlin is senior vice president and head of technical operations at Senti Biosciences, supporting the allogeneic NK-CAR programs. Before joining Senti, he led the PD groups at PACT Pharma (non-viral process for generating autologous neoTcR+ T cells), Poseida (non-viral process for generating autologous CAR-T’s), and Novartis (clinical and commercial manufacturing process for Kymriahâ). His experience covers over 25 years of various approaches to harness the immune response to treat cancer and infectious disease, starting with Proleukinâ rIL-2 (aldesleukin; Chiron), Oncolytic adenovirus (Onyx), Listeria-based cancer vaccines (Cerus), and CCR5 knockout CD4+ T cells for HIV+ patients (Sangamo).  In addition, he led the implementation of AAV clinical manufacturing to support the Hemophilia, LSD, and neurodegenerative disease programs.

MODERATOR BIO

Ben Locwin, Ph.D., Vice President, Project Solutions, Black Diamond Networks
Dr. Locwin has been at the forefront of innovation in the industry and has worked on developing various treatments across many therapeutic areas. In his work, he is often called upon by investors to forecast the “next big thing.” Dr. Locwin is also a professor of clinical medicine and healthcare economics. He has been featured in The Wall Street Journal, Forbes, USA Today, Der Spiegel, The Associated Press, and other top-tier media.